NasdaqGM:ADMABiotechs
Why ADMA Biologics (ADMA) Is Up After FDA Clears Yield-Enhanced Production and Revenue Guidance Boost
ADMA Biologics recently reported strong third-quarter results, with US$134.22 million in revenue and net income of US$36.43 million, while also raising its fiscal 2025 and 2026 revenue guidance to at least US$510 million and US$630 million, respectively.
A major development was the FDA lot release authorization for yield-enhanced production batches, anticipated to meaningfully improve manufacturing efficiency and expand gross margins starting from the fourth quarter of 2025.
Next, we will...